articleThe Lancet OncologyJun 1, 2020Closed access

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

MSMichael S. LeeBRBaek‐Yeol RyooCHChih‐Hung HsuKNKazushi NumataSSStacey Stein

University of North Carolina at Chapel Hill · University of Ulsan · +9 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

566
total citations
FWCI
46.12
Percentile
100%
References
38
Citations per year

Authors

40

Topics & keywords

Topics
Keywords
  • Atezolizumab
  • Bevacizumab
  • Medicine
  • Hepatocellular carcinoma
  • Internal medicine
  • Oncology
  • Response Evaluation Criteria in Solid Tumors
  • Population
No related works found for this paper.

Funding